Biomarkers of inflammation predict both vascular and non-vascular mortality in older men

European Heart Journal

Volumn 29, Issue 6, 2008, Pages 800-809

  Clarke, Robert ^a   Emberson, Jonathan R ^a   Breeze, Elizabeth ^b   Casas, Juan P ^c   Parish, Sarah ^a   Hingorani, Aroon D ^b   Fletcher, Astrid ^c   Collins, Rory ^a   Smeeth, Liam ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

C reactive protein; Lipids; Prediction of mortality in old age

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ARTICLE; DIAGNOSTIC VALUE; DISEASE MARKER; ELDERLY CARE; HUMAN; INFLAMMATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; RISK FACTOR; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FIBRINOGEN; HUMANS; LONDON; MALE; MYOCARDIAL ISCHEMIA; PROSPECTIVE STUDIES; RISK FACTORS; SERUM ALBUMIN; SURVIVAL RATE; VASCULITIS;

EID: 41149179542     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn049     Document Type: Article

References (30)

1. Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 2005;352:1685-1695.
2. Ridker PM. Role of inflammatory biomarkers in prediction of coronary heart disease. Lancet 2001;358:946-948.
3. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F, Centers for Disease Control Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
4. Libby P, Ridker PM. Inflammation and atherosclerosis: from population biology to bench research to clinical practice. J Am Coll Cardiol 2006;48:A33-A46.
5. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979.
6. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565.
7. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results for a large cohort study in southern Germany. Circulation 2004;109:1349-1353.
8. Pai JK, Pischon T, Ma J et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004;351:2599-2610.
9. Ballantyne CM, Hoogeveen RC, Bang H et al. Lipoprotein associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004;109:837-842.
10. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-1397.
11. Best LG, Zhang Y, Lee ET, Yeh JL, Cowan L, Palmieri V, Roman M, Devereux RB, Fabsitz RR, Tracy RP, Robbins D, Davidson M, Ahmed A, Howard BV. C-reactive protein as a predictor of cardiovascular risk in a population with a high risk prevalence of diabetes: the Strong Heart Study. Circulation 2005;112:1289-1295.
12. Laaksonen DE, Niskanen L, Nyyssonen K, Punnonen K, Tuomainen TP, Salonen JT. C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study. Eur Heart J 2005;26:1783-1789.
13. Boekholdt SM, Hack CE, Sandhu MS, Luben R, Bingham SA, Wareham NJ, Peters RJ, Jukema JW, Day NE, Kastelein JJ, Khaw KT. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis 2006;187:415-422.
14. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M, Goldbourt U, Willeit J, Kiechl S, Yarnell JW, Sweetnam PM, Elwood PC, Cushman M, Psaty BM, Tracy RP, Tybjaerg-Hansen A, Haverkate F, de Maat MP, Fowkes FG, Lee AJ, Smith FB, Salomaa V, Harald K, Rasi R, Vahtera E, Jousilahti P, Pekkanen J, D'Agostino R, Agostino R, Kannel WB, Wilson PW, Tofler G, Arocha-Piñango CL, Rodriguez-Larralde A, Nagy E, Mijares M, Espinosa R, Rodriquez-Roa E, Ryder E, Diez-Ewald MP, Campos G, Fernandez V, Torres E, Marchioli R, Valagussa F, Rosengren A, Wilhelmsen L, Lappas G, Eriksson H, Cremer P, Nagel D, Curb JD, Rodriguez B, Yano K, Salonen JT, Nyyssönen K, Tuomainen TP, Hedblad B, Lind P, Loewel H, Koenig W, Meade TW, Cooper JA, De Stavola B, Knottenbelt C, Miller GJ, Cooper JA, Bauer KA, Rosenberg RD, Sato S, Kitamura A, Naito Y, Palosuo T, Ducimetiere P, Amouyel P, Arveiler D, Evans AE, Ferrieres J, Juhan-Vague I, Bingham A, Schulte H, Assmann G, Cantin B, Lamarche B, Després JP, Dagenais GR, Tunstall-Pedoe H, Woodward M, Ben-Shlomo Y, Davey Smith G, Palmieri V, Yeh JL, Rudnicka A, Ridker P, Rodeghiero F, Tosetto A, Shepherd J, Ford I, Robertson M, Brunner E, Shipley M, Feskens EJ, Kromhout D, Dickinson A, Ireland B, Juzwishin K, Kaptoge S, Lewington S, Memon A, Sarwar N, Walker M, Wheeler J, White I, Wood A. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005;294:1799-1809.
15. Cushman M, Arnold AM, Psaty BM, Manolio TA, Kuller LH, Burke GL, Polak JF, Tracy RP C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 2005;112:25-31.
16. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilahn EN, Kuller LH. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997;17:1121-1127.
17. van der Meer IM, de Maat MP, Kiliaan AJ, van der Kuip DA, Hofman A, Witteman JC. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch Intern Med 2003;163:1323-1328.
18. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal probrain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005;293:1609-1616.
19. Clarke R, Emberson JR, Parish S, Palmer A, Shipley M, Linksted P, Sherliker P, Clark S, Shipley M, Armitage J, Fletcher A, Collins R. Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older men. Arch Int Med 2007;167:1373-1378.
20. Reid DD, Brett GZ, Hamilton PJS, Jarrett RT, Keen H, Rose G. Cardiorespiratory disease and diabetes in middle aged male civil servants. Lancet 1974;I:469-473.
21. Rose G, Reid DD, Hamilton PJS, McCartney P, Keen H, Jarrett RJ. Myocardial Ischaemia, risk factors and death from coronary heart disease. Lancet 1977;i:105-109.
22. Clarke R, Breeze E, Sherliker P, Shipley M, Youngman L, Fletcher A, Fuhrer R, Leon D, Parish P, Collins R, Marmot M. Design, objectives and lessons from a 25 year follow-up re-survey of survivors in the Whitehall study of London Civil Servants. J Epidemiol Community Health 1998;52:364-369.
23. Clarke R, Breeze E, Youngman L, Sherliker P, Bell P, Shah S, Shipley M, Collins R, Leon D, Marmot M, Fletcher A. Re-survey of the Whitehall study of London civil servants: changes in risk factors for cardiovascular disease during 29 years of follow-up. J Cardiovasc Risk 2000;7:251-257.
24. Youngman LD, Lyons VE, Collins R, Peto R. Problems with mailed whole blood in large-scale epidemiological studies and methods of correction. (Abstract). FASEB J 1993;1:377.
25. Plummer M. Improved estimates of floating absolute risk. Stat Med 2004;23:93-104.
26. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999;150:341-353.
27. Keavney B, Danesh B, Parish S, Palmer A, Clark S, Youngman L, Delépine M, Lathrop M, Peto R, Collins R, on behalf of the International Study of Infarct Survival (ISIS) collaboratorsFibrinogen and coronary heart disease: test of causality by 'Mendelian randomization'. Int J Epidemiol 2006;35:935-943.
28. Danesh J, Collins R, Appleby P, Peto R. Fibrinogen, C-reactive protein, albumin, or white cell count: meta-analyses of prospective studies of coronary heart disease. JAMA 1998;279:1477-1482.
29. Corti MC, Guralnik JM, Salive ME, Sorkin JD Serum albumin and physical disability as predictors of mortality in older persons. JAMA 1994;252:1036-1042.
30. Hazzard WZ. Depressed albumin and high-density lipoprotein cholesterol: signposts along the final common pathway of frailty. J Am Geriatr Soc 2001;49:1253-1254.